Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats.
1. Diabetic neuropathy is a many faceted complication of both type I and II diabetes. The aim of the present study was to investigate the effects of bendazac lysine (BDL), an anticataract drug, on experimental diabetic peripheral neuropathy (DPN) in rats. 2. Diabetes was induced in rats by intraperitoneal injection of 75 mg/kg streptozotocin (STZ) dissolved in 0.1 mol/L citrate buffer (pH 4.4). Bendazac lysine was administered to rats at doses of 50, 100 and 200 mg/kg twice a day for 12 weeks. 3. Diabetic rats without treatment showed hypopraxia, polydipsia, polyuria, slow weight gain, cataract, increased tail-flick threshold temperature, decreased motor nerve conduction velocity (nd induced pathological morphological changes of myelinated nerve fibres. All these symptoms were ameliorated in diabetic rats treated with BDL. Bendazac lysine ameliorated the blood glucose concentration, glycosylated haemoglobin levels and insulin levels in the plasma of diabetic rats, reduced aldose reductase activity in erythrocytes and advanced glycation end-products in both nerves and serum and increase the activity of glutathione peroxidase in the nerves and Na(+)/K(+)-ATPase in the nerves and erythrocytes. 4. Bendazac lysine exerts its protective effects against the progression of diabetic peripheral neuropathy in STZ-diabetic rats through multiple mechanisms and is a potential drug for the prevention of deterioration in DPN.
Yu
Jun-Xian
JX
Department of Pharmacology, Nanjing Medical University, Nangjing, PR China.
Yin
Xiao-Xing
XX
Shen
Jian-Ping
JP
Qiu
Jun
J
Yin
Hong-Lin
HL
Jiang
Shao-Jun
SJ
D000449:Aldehyde Reductase / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000473:pathology*; D003929:Diabetic Neuropathies / Q000517:prevention & control*; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000097:blood; D007191:Indazoles / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D009186:Myelin Sheath / Q000473:pathology; D010146:Pain / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013497:Sural Nerve / Q000473:pathology
D000449:Aldehyde Reductase; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D005979:Glutathione Peroxidase; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D007191:Indazoles; D007328:Insulin; D000254:Sodium-Potassium-Exchanging ATPase; C036067:bendazac lysine